Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM04690 (lorecivivint) in knee osteoarthritis
NCT03727022Phase 2Completed
- Sponsor
- Biosplice Therapeutics
- Start
- Nov 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing 0.07 mg SM04690 with Vehicle (Placebo) (2 arms). Primary endpoint: Change in Total Bone Mineral Density From Baseline in the Treated Knee by qCT at 52 weeks. Started Nov 2018; status: completed.
02
Drugs
lorecivivint
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03727022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727022.